Alector Prices $75.03M Common Stock Offering Of 36.6M Shares At $2.05/Share

Alector Reports Third Quarter 2026 Financial Results

Alector, Inc. reported its third-quarter 2026 financial results, highlighting a net income of $124.6 million driven by the recognition of deferred revenue following the termination of its agreement with GSK.

8-K filing — Alector, Inc. (ALEC)

Filed: 2026-10-16 AccNo: 0001193125-26-424204 Size: 423 KB Item 1.01: Entry into a Material Definitive Agreement Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Fastenal To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Thursday

Analysts raised targets for TSM, MRNA, ALEC and WMT; cut AZZ, ARRY and ALGN targets, upgrading ARRY/WMT and downgrading ALGN.

HC Wainwright & Co. Maintains Buy on Alector, Raises Price Target to $8

HC Wainwright & Co. analyst Andrew S. Fein maintains Alector (NASDAQ:ALEC) with a Buy and raises the price target from $5 to $8.

Morgan Stanley Maintains Underweight on Alector, Raises Price Target to $3

Morgan Stanley analyst Sean Laaman maintains Alector (NASDAQ:ALEC) with a Underweight and raises the price target from $2 to $3.

Alector shares are trading higher after the company announced an exclusive global licensing agreement granting Genentech worldwide rights to develop and commercialize its AL050 program.